HOLIDAY SHIPPING UPDATE: All delivery service requests will not be processed on Friday April 2, 2021 as it is Good Friday holiday. Regular delivery schedule will resume the next business day.
Anti-phospho-HER2 (Tyr877)(E27-65R)

Anti-phospho-HER2 (Tyr877)(E27-65R)

  • $270.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Rabbit Polyclonal Antibody

Species :

Tag :

Expression System:

Sequence :

Specificity :Recognizes the HER2 protein phosphorylated at tyrosine 877

Cited Applications :WB, IHC

Cross Reactivity :Human, Mouse and Rat

Host / Isotype / Clone# :Rabbit, IgG

Immunogen :Synthetic phospho-peptide corresponding to amino acid residues surrounding Tyr877

Purification :Affinity chromatography

Stability :Store at 4oC (add 0.1% NaN3) for several months, and at -20oC for longer periods. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Sample Data :Western blot analysis of extracts from MDA-MB-231 cells untreated or treated with EGF (200ng/ml, 5min), using HER2 antibody (lanes 1 and 2) and anti-phospho-HER2 (Tyr877) antibody (lanes 3 and 4).

Sample Data :Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using anti-phospho-HER2 (Tyr877) antibody.

Scientific Background :HER2 is a glycoprotein tyrosine kinase receptor that has extensive homology to the epidermal growth factor receptor. Overexpression of HER2 in NIH 3T3 cells results in cellular transformation and tumorigenesis (1). HER2 is amplified in about 30% of primary human breast malignancies and is associated with the most aggressive tumors. These tumors characteristically display uncontrolled proliferation, resistance to apoptosis and increased motility (2). HER2 activity is regulated in part by phosphorylation at Tyr877.

References :
1. Hudziak, R M. et al: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7159-63.

2. Badache, A. et al: The ErbB2 Signaling Network as a Target for Breast Cancer Therapy. J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):13-25.

Product Sheets (By Lot #) :

J1178-9.pdf

Research Areas :AKT/PKB Pathway, Cancer, ERK/MAPK Pathway, Receptor Tyrosine Kinases, Cancer, AKT/PKB Pathway, ERK/MAPK Pathway, Receptor Tyrosine Kinases